Trial Filter

BETA

An intelligent search tool for clinical trials

Sign In
Back|NCT06876662Recruiting
Official Title

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Phase
Phase 4
Sponsor
Eli Lilly and Company
Enrollment
279
Timeline
May 2025 → Dec 2032
About This Study

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Eligibility Criteria

Inclusion Criteria

  • 1Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are:
  • 2receiving study intervention
  • 3in the short-term follow-up period, or
  • 4in the long-term follow-up period

Exclusion Criteria

  • 1Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001

Locations

36 sites participating in this study

The Emory Clinic

Atlanta, Georgia 30322-1013

Recruiting

Jonathon Cohen

Sylvester Comprehensive Cancer Center

Miami, Florida 33136-1002

Recruiting

Alvaro Alencar

Florida Cancer Specialists

Sarasota, Florida 34232-6422

Recruiting

Manish Patel

Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →